Funding for this research was provided by:
Medical Research Council (MR/N028287/1)
Health Technology Assessment Programme (HTA - 12/127/126)
Text and Data Mining valid from 2020-01-14
Received: 13 September 2019
Accepted: 21 December 2019
First Online: 14 January 2020
Ethics approval and consent to participate
: The PARAMEDIC2 trial protocol was approved by the South Central–Oxford C Research Ethics Committee and the Medicines and Healthcare Products Regulatory Authority (14/SC/0157). The trial was designed and conducted in accordance with Directive 2001/20/EC of the European Parliament and Council, which was transposed into legislation in the United Kingdom by the Medicines for Human Use (Clinical Trials) Regulations. Patients or their representatives provided written consent. Additional ethics approval was not sought to perform this secondary analysis.
: Not applicable.
: The authors declare that they have no competing interests.